About Fibrocell Science
Fibrocell Science is a company based in Exton (United States) founded in 1995 was acquired by Castle Creek Pharma in September 2019. Fibrocell Science has raised $34.66 million across 20 funding rounds from investors including Castle Creek Pharma, Precigen and EBMRF. Fibrocell Science operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Exton, United States
- Stage Public
- SectorsHealthcare
- Website fibrocell.com
- Social LinkedIn X
- Acquired by Castle Creek Pharma (Sep 2019)
- Legal Name Fibrocell Science, Inc.
- Total Equity Funding$34.66M (USD)
in 20 rounds
- Latest Funding Round$900K (USD), Post-IPO
Dec 2018
- InvestorsCastle Creek Pharma
& 3 more
- Acquired byCastle Creek Pharma
(Sep 2019)
Funding Insights of Fibrocell Science
Fibrocell Science has successfully raised a total of $34.66M across 20 strategic funding rounds. The most recent funding activity was a Post-IPO round of $900 thousand completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $34.66M
- Total Rounds 20
- Last Round Post-IPO — $900,000
- First Round $10.1M
(Jul 2002)
- Investors Count 3
Latest 10 of 20 funding rounds of Fibrocell Science with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2018 | $900,000 | Post-IPO | – | – | |
| Jul 2018 | $3.06M | Post-IPO | – | – | – |
| May 2018 | $5.09M | Post-IPO | – | – | – |
| Aug 2016 | $18.1M | Post-IPO | – | – | – |
| Jul 2015 | $15M | Post-IPO | – | – | – |
| Sep 2013 | $50.5M | Post-IPO | – | – | – |
| Oct 2012 | $45M | Post-IPO | – | – | |
| Jul 2012 | $9.1M | Post-IPO | – | – | – |
| May 2012 | $3.35M | Post-IPO | – | – | – |
| May 2012 | $3.35M | Post-IPO | – | – | – |
4 investors in total: 4 institutional.
Investors in Fibrocell Science
Fibrocell Science has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include Castle Creek Pharma, Precigen and EBMRF.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Research funding and awareness for Epidermolysis Bullosa are supported. | – | ebmrf.org | Los Angeles, United States | |
Research funding is provided to cure Epidermolysis Bullosa. | – | ebresearch.org | New York, United States | |
Gene and cell therapy biopharmaceutical company focused on immuno-oncology, autoimmune, and infectious diseases | 1998 | precigen.com | Germantown, United States | |
Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders | 2015 | castlecreekpharma.com | Basking Ridge, United States |
Investor details for Fibrocell Science
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Fibrocell Science
12 people are tracked at Fibrocell Science (10 in leadership, 1 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Brad Middlekauff | Chief Legal Officer | Leadership |
Andrea Kistner | VP, Finance | Leadership |
Edward Russell | Senior Director Of Human Resources | Leadership |
Gregory MacMichael | CTO | Leadership |
Matthew Gantz | President & CEO | Leadership |
Robin Blumenthal | Senior Director, Clinical Operations | Leadership |
Mary Spellman | Chief Medical Officer | Leadership |
Greg Wujek | Chief Commercial Officer | Leadership |
Clarence W. Baker | Director, Quality Technology | Leadership |
Anthonius Kley | Facilities Director | Leadership |
Jeff Aronin | Castle Creek Biosciences Founder & Chairman | Board & advisors |
Karl Hyk | Sr. Clinical Trial Manager | Team |
Complete people profiles for Fibrocell Science
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Fibrocell Science
5 dated milestones of Fibrocell Science across 24 years, from founding to its latest funding, stage changes and deals.
- Founded Fibrocell Science is founded.
- Funding First funding round of $10.1M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $900K.
- Exit Acquired by Castle Creek Pharma.
Competitors of Fibrocell Science
Fibrocell Science operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| horizontherapeutics.com | 2008 | Dublin, Ireland | $61.78M | – | Developer of drugs for treating rare and autoimmune diseases | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| chimerix.com | 2002 | Durham, United Kingdom | $95.23M | 72 | Antiviral oral therapeutics are developed for infectious diseases and cancers. |
Detailed competitors of Fibrocell Science
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Fibrocell Science
Complete news archive for Fibrocell Science
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Fibrocell Science
10 companies that operate in the same segment as Fibrocell Science (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Fibrocell Science
Fibrocell Science was founded in 1995 and raised its 1st funding round 7 years after it was founded.
Fibrocell Science is headquartered in Exton, United States. It is registered at Exton, Pennsylvania, United States.
Fibrocell Science is a funded company, having raised a total of $34.66M across 20 funding rounds to date. The company's 1st funding round was a Post-IPO of $3.35M, raised on Jul 2002.
Fibrocell Science was founded in 1995 and is headquartered in Exton, United States. Autologous cell and gene therapies are developed by the company for conditions affecting the skin, connective tissue, and joints. The lead product candidate, FCX-007, targets linear scleroderma through gene therapy. Additional candidates for arthritis treatments are under development in the biotechnology sector.
Fibrocell Science's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Fibrocell Science has 4 investors. Key investors include Castle Creek Pharma, Precigen, EBMRF, and EB Research Partnership.
Fibrocell Science operates through Fibrocell Science, Inc..
Yes. Fibrocell Science was acquired by Castle Creek Pharma in September 2019.